Bausch Health Companies Inc. (TSX:BHC)
7.89
+0.08 (1.02%)
At close: Feb 2, 2026
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $1.93B USD in the quarter ending September 30, 2025, a decrease of -19.87%. This brings the company's revenue in the last twelve months to $9.27B, up 5.15% year-over-year. In the year 2024, Bausch Health Companies had annual revenue of $9.63B with 9.91% growth.
Revenue (ttm)
$9.27B
Revenue Growth
+5.15%
P/S Ratio
0.21
Revenue / Employee
$447.99K
Employees
20,700
Market Cap
2.92B CAD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
| Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
| Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
| Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
| Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
| Dec 31, 2019 | 8.60B | 221.00M | 2.64% |
| Dec 31, 2018 | 8.38B | -344.00M | -3.94% |
| Dec 31, 2017 | 8.72B | -950.00M | -9.82% |
| Dec 31, 2016 | 9.67B | -773.00M | -7.40% |
| Dec 31, 2015 | 10.45B | 2.24B | 27.31% |
| Dec 31, 2014 | 8.21B | 2.44B | 42.23% |
| Dec 31, 2013 | 5.77B | 2.29B | 65.77% |
| Dec 31, 2012 | 3.48B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Curaleaf Holdings | 1.78B |
| Trulieve Cannabis | 1.66B |
| Green Thumb Industries | 1.61B |
| Verano Holdings | 1.16B |
| Cresco Labs | 921.56M |
| Knight Therapeutics | 413.85M |
| Aurora Cannabis | 367.13M |
| Canopy Growth | 278.61M |
Bausch Health Companies News
- 13 hours ago - Bausch (BHC) Faces Legal Settlement Over Generic Drug Price Fixing - GuruFocus
- 10 days ago - Bausch Health: RED-C Failure Leaves Blockbuster Xifaxan Without A Successor - Seeking Alpha
- 10 days ago - Bausch Health (BHC) Faces Setback with Phase 3 Trial Results - GuruFocus
- 10 days ago - Bausch Health Companies Becomes Oversold (BHC) - Nasdaq
- 10 days ago - Stocks making the biggest moves midday: Fortinet, Moderna, Intel, Bausch Health & more - CNBC
- 10 days ago - Bausch Health Companies (BHC) Shares Cross Below 200 DMA - Nasdaq
- 10 days ago - Bausch Health (BHC) Falls as Phase 3 Trials Miss Primary Endpoint - GuruFocus
- 10 days ago - Bausch Health falls on phase 3 failure of liver disease complications drug - Seeking Alpha